Most health care industry stakeholders consider many options in preventive care to be a good investment, shown to improve health and quality of life while also delivering short- and long-term cost savings for health care systems. But even as many new products and strategies in preventive care have been introduced in recent years, payer adoption and reimbursement for these options is often limited, creating challenges for health care systems and entire communities working to expand strategies in disease prevention.
In this Medical Economics article, Michele Pistollato, Rajini Jayasuriya, and Elaine Damato assess a range of strategies, including vaccination and wellness programs and technologies such as genetic testing, and consider how payer support for different options might change in the years ahead.
